CytomX Therapeutics, Inc. (CTMX) Free cash flow 2016–2025
CytomX Therapeutics, Inc. (CTMX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$75.8MFY2025 · since FY2016: -$4.2M → -$75.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$75.8M | +12.4% |
| FY2024 | -$86.5M | -52.2% |
| FY2023 | -$56.9M | +49.5% |
| FY2022 | -$112.5M | +6.7% |
| FY2021 | -$120.6M | -4189.5% |
| FY2020 | $3.0M | +102.0% |
| FY2019 | -$144.0M | -81.5% |
| FY2018 | -$79.3M | -147.0% |
| FY2017 | $168.8M | +4111.7% |
| FY2016 | -$4.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice